Research Progress of Proteasome Inhibitor MG132 in Treatment of Gynecologic Malignant Tumors

The ubiquitin-proteasome system (UPS) is the primary mechanism for intracellular protein degradation, crucial in oncogenesis and tumor progression. Proteasome inhibitors disrupt UPS-mediated proteolysis, effectively inhibiting neoplastic cell proliferation, and have become established therapeutic targets in oncology. Gynecologic malignant tumors pose a significant threat to women's reproductive health globally. Among proteasome inhibitors, MG132 has garnered extensive attention in gynecologic oncology due to its multifaceted mechanisms, including cell cycle regulation, NF-κB signaling inhibition, and modulation of p53 activity. This review consolidates recent research on the therapeutic potential of MG132 in gynecologic malignant tumors, with a focus on its molecular mechanisms of action.